P272 Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results

10.1016/s0960-9776(11)70214-4 ◽

2011 ◽

Vol 20 ◽

pp. S65 ◽

Author(s):

J. O'Shaughnessy ◽

C. Brownstein ◽

S. Hörsch ◽

N. Scotto

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

10.1158/0008-5472.sabcs10-s4-2 ◽

2010 ◽

Author(s):

J O'Shaughnessy ◽

D Paul ◽

C Stokoe ◽

J Pippen Jr ◽

JL Blum ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.500 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 500-500 ◽

Author(s):

J. E. Pippen ◽

D. Paul ◽

C. T. Stokoe ◽

J. L. Blum ◽

L. Krekow ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Ki 67 ◽

Phase Iii Study

Download Full-text

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

British Journal of Cancer ◽

10.1038/bjc.2017.158 ◽

2017 ◽

Vol 117 (2) ◽

pp. 164-170 ◽

Author(s):

Dimitrios Mavroudis ◽

Emmanouil Saloustros ◽

Ioannis Boukovinas ◽

Pavlos Papakotoulas ◽

Stylianos Kakolyris ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Research Group ◽

Interim Analysis ◽

Phase Iii ◽

Node Negative ◽

Oncology Research ◽

Phase Iii Study

Download Full-text

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.056 ◽

2021 ◽

Vol 32 ◽

pp. S37-S38

Author(s):

O. Metzger ◽

C. Lambertini ◽

I.E. Krop ◽

G. Lewis Phillips ◽

C.M. Perou ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Biomarker Analysis ◽

Phase Iii Study

Download Full-text

VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.800 ◽

2021 ◽

Author(s):

J. Huober ◽

C.H. Barrios ◽

N. Niikura ◽

M. Jarzab ◽

Y-C. Chang ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.429 ◽

2021 ◽

Vol 32 ◽

pp. S425

Author(s):

P.H. Cottu ◽

F. Dalenc ◽

S. Chabaud ◽

D. Allouache ◽

D. Cameron ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Hormone Therapy ◽

Early Breast Cancer ◽

Subgroup Analysis ◽

Phase Iii ◽

Adjuvant Hormone Therapy ◽

Breast Cancer Subgroup ◽

Phase Iii Study

Download Full-text

Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0042-106209 ◽

2016 ◽

Vol 76 (05) ◽

pp. 542-550 ◽

Author(s):

L. Schröder ◽

B. Rack ◽

H. Sommer ◽

J. Koch ◽

T. Weissenbacher ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Toxicity Assessment ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)

European Journal of Cancer ◽

10.1016/j.ejca.2021.07.033 ◽

2021 ◽

Vol 156 ◽

pp. 138-148

Author(s):

Volker Möbus ◽

Hans-Joachim Lück ◽

Ekkehart Ladda ◽

Peter Klare ◽

Marcus Schmidt ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Randomised Trial ◽

Phase Iii ◽

Download Full-text

Abstract OT-01-02: Adaptlate -a randomized, controlled, open-label, phase-iii trial on adjuvant dynamic marker - adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, hr+/her2- early breast cancer

10.1158/1538-7445.sabcs20-ot-01-02 ◽

2021 ◽

Author(s):

Oleg Gluz ◽

Tom Degenhardt ◽

Norbert Marschner ◽

Matthias Christgen ◽

Hans Heinrich Kreipe ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Adjuvant Endocrine Therapy ◽

Phase Iii ◽

Phase Iii Trial ◽

Randomized Controlled ◽

Open Label Phase

Download Full-text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.072 ◽

2018 ◽

Vol 93 ◽

pp. 19-27 ◽

Author(s):

X. Pivot ◽

I. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Reference Product ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text